Laekna, Inc. (2105.HK)

6.740 -0.040 (-0.59%) At close: 04:08PM HKT

Laekna, Inc.

3-2-467, 5 Xingbin Road
Lin Li Center Sino-Italy Ningbo Ecological Park
Yuyao
China

https://www.laekna.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 89

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Xiangyang Lu Ph.D.	CEO & Executive Chairman	2.97M	N/A	1965
Mr. Kwok Keung Chau ACCA, C.F.A., HKICPA	Chief Financial Officer	199.15k	N/A	1976
Ms. Ling Xie	Senior VP of Head of Operation & Executive Director	2.53M	N/A	1972
Dr. Xiang-Ju Gu Ph.D.	Executive Director & Chief Scientific Officer	2.71M	N/A	1967
Mr. Yong Yue	Chief Medical Officer	N/A	N/A	1962
Mr. Chenyu Ke	Joint Company Secretary	N/A	N/A	N/A
Ms. Wing Nga Ho	Joint Company Secretary	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

Corporate governance

Laekna, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.